- Clinical Trials
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£998GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- March 2025
- 180 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- August 2024
- 121 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- February 2024
- 180 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- August 2022
- 117 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2023
- 147 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €14255EUR$14,995USD£11,976GBP

Dyskinesia is a neurological disorder characterized by involuntary movements of the body. Dyskinesia is often caused by long-term use of certain drugs, such as antipsychotics, and can be treated with drugs that reduce the severity of the symptoms. Dyskinesia drugs are part of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders, such as Parkinson's disease, Alzheimer's disease, and epilepsy.
Dyskinesia drugs are typically used to reduce the severity of symptoms, such as tremors, muscle spasms, and difficulty speaking. These drugs can also help improve coordination and balance, as well as reduce fatigue. Commonly prescribed dyskinesia drugs include levodopa, amantadine, and anticholinergics.
Some companies in the dyskinesia drug market include AbbVie, Pfizer, Merck, and Novartis. These companies produce a variety of drugs used to treat dyskinesia, including levodopa, amantadine, and anticholinergics. Show Less Read more